Barnes Grp Stock Price, News & Analysis

BioArctic AB (BIOA) has received regulatory approval in Spain and Poland to expand its EXIST Phase 2a study of exidavnemab to include Multiple System Atrophy (MSA) patients. The study will now add 12 MSA patients to the existing 24 Parkinson's Disease participants.

Exidavnemab is a monoclonal antibody targeting alpha-synuclein aggregates, being developed as a potential disease-modifying treatment for neuronal synuclein diseases. The study will evaluate safety, tolerability, and various biomarkers in plasma, cerebrospinal fluid, and through digital measurements.

MSA is described as a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems, with no current cure or treatment to slow progression. The condition impacts basic functions including breathing, digestion, and bladder control.

Integrum AB (INTEG) has appointed Martin Hillsten as its new CEO, effective immediately, replacing acting CEO Scott Flora. Hillsten, who previously served as CEO of Integration Diagnostics, brings 20 years of life sciences industry experience with expertise in implant products and diagnostic imaging. The company is implementing a strategic shift to accelerate market penetration of the OPRA® Implant System in the US and priority European markets.

The new strategy focuses on selected Centers of Excellence, strengthened aftermarket approach, and operational optimization expected to yield cost savings of up to SEK 20 million annually by early 2026. Flora will continue supporting US marketing activities in an advisory role while maintaining his position on the Board of Directors.

ETQ, a Hexagon company and provider of quality management solutions, reported strong performance in Q1 2025, meeting both top and bottom-line goals. The company's ETQ Reliance® platform received eight G2 Winter 2025 Software awards, including leadership recognition across enterprise and midmarket segments. ETQ appointed Brandon McAllister as Chief Revenue Officer to oversee sales operations and expansion strategies.

The company expanded its global customer base across various sectors including heavy industry, life sciences, and manufacturing, adding notable clients like Ace International, RCA, and Discovery. Existing customers like 3D Systems, Emerson Electric, and PPG increased their platform usage. ETQ also released 2025 predictions highlighting trends in AI, EHS, connected workers, labor shortages, and product recall prevention.

TrustPoint has secured a $1.2 million SBIR Phase II contract from the US Navy's Naval Air Systems Command (NAVAIR) to deliver and demonstrate first-of-its-kind C-band GNSS receivers. The company will partner with Hexagon | NovAtel and Hexagon US Federal to execute this groundbreaking project.

The collaboration combines TrustPoint's C-band services with NovAtel's GNSS receiver technology to develop resilient Positioning, Navigation, and Timing (PNT) solutions for military applications. The project aims to integrate TrustPoint's C-band GNSS services into advanced anti-jam receivers, offering GPS-independent capabilities for mission continuity in contested environments.

ASSA ABLOY (NASDAQ Stockholm: ASSA_B), a global leader in access solutions with $15.6 billion in annual sales and 63,000 employees, has acquired Pedestal PRO, a Utah-based manufacturer of access control mounting solutions.

Founded in 2002, Pedestal PRO specializes in designing and manufacturing universal and device-specific mounting solutions for security systems integrators and professionals globally. The company also offers custom design and fast-track fabrication services.

The acquisition strengthens ASSA ABLOY's presence in mature markets by enhancing its core business, as Pedestal PRO's products integrate seamlessly with ASSA ABLOY solutions. The founders and leadership team of Pedestal PRO, including CEO Pike Goss, will remain in place to support continued growth.

Hexagon AB (HEXA) has announced key leadership changes in its Manufacturing Intelligence division. Andreas Renulf will assume the role of President effective May 1, 2025, reporting to interim President and CEO Norbert Hanke. Renulf, who joined Hexagon in January 2024 as COO and Head of Machine Control for the Geosystems division, brings extensive experience from Trelleborg and ABB.

The current President, Josh Weiss, is departing to join another company and will facilitate the transition through May 2025. During his ten-year tenure at Hexagon, Weiss notably improved profitability and cash conversion in the Manufacturing Intelligence division. Renulf's appointment comes with expectations to drive growth and operational excellence, particularly in robotics and autonomy optimization for customer product lifecycles.

Lennar (NYSE: LEN) has partnered with Dandelion Energy to implement one of the largest residential geothermal deployments in US history. The collaboration will integrate Dandelion's geothermal systems into over 1,500 new Lennar homes in Colorado over the next two years.

Homeowners are expected to save approximately $30 million over 20 years compared to air-source heat pumps, offering the lowest monthly energy bills. The initiative benefits from Colorado's state tax credit and Xcel Energy's geothermal programs, significantly reducing up-front costs for homebuilders.

The project aligns with Colorado's clean energy transition goals, promising reduced carbon emissions and lower energy costs. According to the Department of Energy, widespread adoption of geothermal heat pumps could eliminate the need for 24,500 miles of new grid transmission lines.

BioArctic AB (BIOA) announced that the European Commission (EC) has referred the marketing authorization approval decision for lecanemab, their Alzheimer's treatment, to the Appeal Committee. This follows the positive opinion received from the Committee for Medicinal Products for Human Use (CHMP) in February 2025.

If approved, the authorization would extend to all 27 EU member states, plus Iceland, Liechtenstein, and Norway. The drug, marketed as Leqembi, is already approved in several major markets including the US, Japan, China, and Great Britain.

Leqembi was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease. While Eisai manages clinical development and global commercialization, BioArctic retains rights to commercialize Leqembi in the Nordic region jointly with Eisai.

Integrum AB (Nasdaq First North: INTEG B) has announced a new compensation package for Board Director and Acting CEO Scott Flora, focusing on performance-based incentives during the company's strategic transition. The package includes 200,000 Stock Appreciation Rights (SARs) with a maximum compensation of SEK 60 per SAR and a base price of SEK 29.30.

The SARs will vest at a rate of 20% every three months starting June 1, 2025, and can be exercised between September 1-October 31, 2026. Unvested SARs will lapse without payment. The company maintains flexibility to pay in either stock or cash. As part of this restructuring, Flora's fixed compensation will be reduced. This adjustment aligns with the company's executive compensation guidelines approved at the latest shareholders' meeting.